GlucoGuard Receives $43 Million Enterprise Valuation Research Report
- Research report values company at $43 million enterprise valuation
- Large market opportunity with potential revenues of $360-720 million in the US
- Negotiations underway for EU licensing rights with upfront payments and royalties
- Development of AI and predictive learning software components for glucose monitoring
- Progress on Dexcom APP integration and Arete Biosciences development contract
- Valuation assumes full dilution for required developmental capital
- Technology and AI components still in development phase
- Company requires additional capital formation
Del Mar, California--(Newsfile Corp. - June 10, 2025) - Harbinger Research, LLC an independent equity research firm with a focus on the small cap and microcap stocks, announced today that it has published a new research report on American Diversified Holdings Corporation/GlucoGuard (OTC Pink: ADHC).
The report includes a valuation analysis, multi-year financial forecast model, and a value estimate of the Company and its shares. The report puts a fully diluted price target of .0012 equivalent to a
As the development process continues further Intellectual Property filings with the USPTO is anticipated further enhancing GlucoGuards' valuation proposition.
A main catalyst for GlucoGuards valuation will be fully described in future releases with a full analysis of the artificial intelligence and predictive learning aspect of the Bio Tracking and recording of blood Glucose levels.
To access the research report, please visit the Harbinger Research website at:
"Management views the
Key Aspects of the Report
537mm Diabetic Patients Worldwide.
37 mm Diabetic Patients In the US.
3.7 Type 1 Diabetics in the US.
190k to 380K Potential Patients in the US.
a potential market of
$360 M M to$720M M in revenues.
IN ADDITIONAL NEWS
ADHC is in negotiations for a strategic partnership to license the GlucoGuard Technology to the Eurpean Union for upfront cash payments, milestone cash payments and cash payment royalties from revenues.
Arete Biosciences development contract has been initially funded and is expected to expand into patient studies.
ADHC 6-15-25 Quartely disclosure filing is expected to be filed this week ahead of the deadline.
Dexcom APP integration and AI software system is under review and should be proceeding to the next phase in the near term.
Patent Counsel is updating GlucoGuards' IP with the USPTO.
Shareholders should anticipate and continual stream of announcements on these developments and more in the near future.
About Harbinger Research, LLC
Harbinger Research, LLC is one of a new breed of issuer-sponsored research boutiques, providing unbiased equity research coverage to smaller issuers that cannot attract research coverage from traditional brokerage firm's research departments. Our mission is to help both investors and public issuers by improving the availability of issuer information and by providing sound, unbiased analysis of our issuer clients' businesses, industries, and current market valuation.
The policies of Harbinger Research, LLC require that all personnel strictly adhere to the CFA Institute's Code of Ethics and Standards of Professional Conduct, and its Best Practice Guidelines Governing Analyst / Corporate Issuer Relations. Please see www.cfainstitute.org for more information.
To view our disclosures and disclaimers, or for more information, visit www.harbingerresearch.com.
Harbinger Research, LLC Brian Connell, CFA Senior Research Analyst brian@harbingerresearch.com.
ABOUT GLUCOGUARD
GlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com.
Contact:
Phone: 817-525-0057
Email: info@GlucoGuardSleep.com
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/255016_6d0a10f01418bade_001full.jpg
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/254131_81935201249818a5_002full.jpg
ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
INVESTOR HOTLINE 858-325-7098
Email: JC@American-Diversified.com ; ADHCInvestor@Yahoo.com
SOCIAL MEDIA
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
SOURCE: American Diversified Holdings Corporation
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255016
FAQ
What is the enterprise valuation given to GlucoGuard (ADHC) in the research report?
What is the market size and revenue potential for GlucoGuard's technology?
What are the key developments mentioned for GlucoGuard (ADHC)?
How does GlucoGuard's technology address diabetes management?
What potential dilution factors should ADHC investors consider?
